首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Molecular Cancer Therapeutics

Molecular Cancer Therapeutics杂志,由American Association for Cancer Research Inc.出版,于2001年创刊,Monthly,出版语言English,ISSN:1535-7163,E-ISSN:1538-8514。

投稿咨询
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
6.9
CiteScore
9.5
期刊收录
SCI、SCIE

Molecular Cancer Therapeutics(中文译名:《分子癌症治疗》),ISSN:1535-7163,EISSN:1538-8514,是American Association for Cancer Research Inc.出版的国际性学术期刊,创刊于2001年,以Monthly形式稳定发行,2026年总发文量约154篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达6.9,2025年期刊CiteScore为9.5,2025年期刊自引率约1.4%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Molecular Cancer Therapeutics长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约3月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、England、Japan、GERMANY (FED REP GER)、South Korea、Netherlands等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMHARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、DANA-FARBER CANCER INSTITUTE、ASTRAZENECA、MEMORIAL SLOAN KETTERING CANCER CENTER、UNIVERSITY OF PENNSYLVANIA等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 55 / 333

83.6

学科:ONCOLOGY SCIE Q1 62 / 333

81.53

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 60 / 328

81.9

学科:ONCOLOGY SCIE Q1 62 / 328

81.25


中国学者近期发文

1
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profile

Author:Tian, Yunan; Zhang, Jieqiong; Sun, Xing; Yang, Changyong; Liao, Cheng

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 3, pp. 371-385. DOI: 10.1158/1535-7163.MCT-24-0680

2
Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistanc

Author:Pulido, Ines; Gunder, Laura C.; Ying, Chenghao; Wang, Yaya; Dai, Yan; Yang, Zimo; Rahnama, Alireza; Li, Jinhua; Sun, Yuetong; Liu, Chuhe; Zhou, Haoxin; Wang, Guoqiang; Foley, Kevin P.; Abdelhady, Khaled; Massad, Malek G.; Prince, Thomas L.; Papautsky, Ian; Ying, Weiwen; Shimamura, Takeshi

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 207-215. DOI: 10.1158/1535-7163.MCT-24-1173

3
SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumor

Author:Peng, Yani; Yang, Changyong; Dong, Liwei; Sun, Xing; Zheng, Wei; Gong, Yanling; Shi, Qing; Ji, Ping; Chen, Simeng; Zhang, Wei; Liao, Cheng

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 322-332. DOI: 10.1158/1535-7163.MCT-24-0752

4
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase-Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficac

Author:Niu, Dun; Zhang, Shaotong; Ma, Xiaozhuang; Wu, Yaran; Zhu, Junshi; Ran, Jianglang; Shan, Meihua; Dai, Xufang; Lu, Lu; Yang, Mingzhen; Lian, Jiqin

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 272-282. DOI: 10.1158/1535-7163.MCT-25-0356

5
A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanis

Author:Zhang, Huan; He, Fufan; Cao, Lei; Ni, Haiqing; Li, Ninghuan; Liu, Yang; Wu, Min; Liu, Ya; Wu, Bing; Li, Li; Wu, Zhihai; Ling, Xiaomin; Zhou, Shuaixiang; Li, Yiming; Deng, Shuxuan; Wu, Weiwei; Chu, Qian

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 21-33. DOI: 10.1158/1535-7163.MCT-25-0425

6
Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradatio

Author:Wang, Han; Luo, Yuxuan; Artham, Sandeep; Wang, Qianqian; Peng, Yi; Yun, Zixi; Li, Xinyue; Wu, Chen; Liu, Zhenghao; Weber-Bonk, Kristen L.; Pai, Chun-Peng; Cao, Yuan; Yue, Jiangan; Park, Sunghee; Keri, Ruth A.; Geng, Lisheng; Mcdonnell, Donald P.; Kao, Hung-Ying; Yang, Sichun

Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 107-124. DOI: 10.1158/1535-7163.MCT-25-0405

7
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Model

Author:Lu, Shan; Pan, Xiao; Volckova, Eva; Shinde, Anjali; Fuller, Schuyler R.; Egan, Regina; Ma, Jianli; Kung, Jong; Ott, Christopher J.; Hata, Aaron N.; Benes, Cyril H.; Kang, Jing X.; Willers, Henning

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 6, pp. 920-930. DOI: 10.1158/1535-7163.MCT-24-0213

8
NOC2L Promotes Paclitaxel Resistance in Various Types of Ovarian Cancers by Decreasing NDUFA4 through Histone Acetylation Suppressio

Author:Gu, Hao; Qi, Suwan; Chen, Jiaying; Wu, Hongqin; Xu, Jianjuan; Feng, Yaling

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 6, pp. 942-956. DOI: 10.1158/1535-7163.MCT-24-0512

9
First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosi

Author:Zhang, Wenjie; Wang, Jing; Shi, Wei; Qiu, Hu; Ke, Shaobo; Tian, Yuanyuan; Gong, Yi; Zhang, Caiyutian; Chen, Jiamei; Wu, Yong; Zhao, Wensi; Chen, Yongshun

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 5, pp. 720-727. DOI: 10.1158/1535-7163.MCT-24-0143

10
Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunit

Author:Lin, Yuan; Lin, Kan; Fu, Qiang; Sun, Xing; Wang, Huan; Su, Lu; Xu, Yanhui; Liao, Cheng

Journal: MOLECULAR CANCER THERAPEUTICS. 2025; Vol. 24, Issue 5, pp. 664-677. DOI: 10.1158/1535-7163.MCT-23-0614


在线咨询

Molecular Cancer Therapeutics

国际简称:MOL CANCER THER参考译名:分子癌症治疗

年发文量:154 CiteScore:9.5 是否预警:否 Gold OA文章占比:36.23% 研究类文章占比:91.56%

杂志社联系方式:AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404

Molecular Cancer Therapeutics